Improves blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg.
This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
Take one tablet of this medicine 5/1000 mg extended-release tablet once daily.
Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin treatment:
The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin treatment
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment according to renal function is required, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter.
No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.
Improves blood glucose control in patients with type 2 diabetes
View approved original textHide original text
This medication is prescribed to assist blood sugar control in patients with type 2 diabetes who use both linagliptin and metformin, complementing dietary and exercise therapy. It effectively lowers blood sugar levels, improving diabetes management and helping to enhance the overall health status of the patient.
How to take
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: linagliptin 5mg and metformin hydrochloride (extended-release) 2000 mg.
This medicine should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it.
Take one tablet of this medicine 5/1000 mg extended-release tablet once daily.
Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin treatment:
The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg.
2. Patients receiving metformin treatment
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride.
- For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia.
- When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary.
- When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should be the patient's current doses of linagliptin and extended-release metformin hydrochloride.
Renal impairment
Because dose adjustment according to renal function is required, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter.
No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2].
In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) ≥ 45mL/min and < 60mL/min or estimated glomerular filtration rate (eGFR) ≥ 45mL/min/1.73m2 and < 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and there are no other conditions that may increase the risk of lactic acidosis.
The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg.
If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.
Precautions
This drug is a medication that helps control blood sugar and contains linagliptin and metformin hydrochloride as active ingredients.
Caution should be taken as a rare side effect called lactic acidosis may occur when using this drug. Lactic acidosis is a dangerous condition caused by excessive accumulation of lactic acid in the body and may require immediate treatment.
This drug should not be used in the following patients: those allergic to this drug or its components, type 1 diabetes patients, patients with severe renal dysfunction, those expected to experience acute renal function changes due to dehydration or severe infection, patients with severe hepatic dysfunction, acute alcohol intoxication patients, those in a very poor nutritional state, or those in specific high-risk situations during pregnancy.
There is a risk of hypoglycemia; thus, blood sugar changes should be closely monitored, especially when used with insulin or sulfonylurea drugs. Additionally, excessive drinking or prolonged fasting should be avoided during metformin treatment.
Kidney function significantly affects the efficacy and safety of this drug; regular kidney function tests should be performed before and during treatment. Caution is needed in the elderly with decreased kidney function, and dose adjustments may be required.
Patients with poor cardiac function or conditions such as acute myocardial infarction or shock should also exercise caution when using this drug.
Before and after examinations using iodinated contrast media, this drug should be temporarily discontinued and restarted only after kidney function has recovered.
This drug should be swallowed whole and not chewed or crushed; however, the drug's coating may pass out in the stool, which is normal.
Women who are pregnant or breastfeeding are advised to avoid using this drug, and if planning to become pregnant, consultation with a physician is necessary.
If any symptoms such as abdominal pain, severe muscle pain, shortness of breath, skin rash, edema, persistent cough, or sudden weight gain occur during use, medical personnel should be informed immediately.
This drug may interact with various medications; therefore, it is essential to inform your doctor or pharmacist if you are taking other medicines.
Elderly patients or those with impaired kidney function should manage their condition through regular examinations and avoid exceeding the maximum dosage.
In case of overdose, measures may be necessary to remove the drug from the gastrointestinal tract, and hemodialysis may be required to eliminate the drug if necessary.
This drug should be stored out of reach of children and kept away from moisture and direct sunlight.
Side effects
Severe lactic acidosis
hypoglycemia
angioedema
urticaria
lactic acidosis
abnormal vitamin B12 absorption test
hypoglycemia
taste disturbance
cough
decreased appetite
Show 120 moreCollapse
diarrhea
constipation
nausea
pancreatitis
vomiting
abdominal pain
oral ulcer
abnormal liver function
hepatitis
itching
erythema
rash
pemphigoid
severe joint pain with disability
rhabdomyolysis
increased lipase
increased amylase
nasopharyngitis
hypersensitivity reaction
constipation
upper abdominal pain
enterocolitis
intestinal obstruction
gastroenteritis
shingles
cystitis
acute pyelonephritis
bronchitis
vestibular neuronitis
sepsis
pneumonia
decreased appetite
dehydration
hyperglycemia
cerebral infarction
stuttering
Alzheimer-type dementia
chest pain
fever
facial swelling
fatigue
chronic obstructive pulmonary disease
asthma
diabetic foot disease
skin lesions
liver metastasis
acute leukemia
basal cell carcinoma
non-small cell lung cancer
malignant pericardial effusion
gastric cancer
rectal cancer
pancreatic cancer
meniscus injury
pneumoconiosis
congestive heart failure
angina pectoris
acute myocardial infarction
unstable angina
cardiac arrest
diabetic retinopathy
acute kidney injury
end-stage renal disease
acute cholangitis
acute cholecystitis
cholangitis
cholelithiasis
dizziness
kidney transplant failure
anxiety
affective disorder
insomnia
depression
contusion
bone contusion
concussion
bone fracture
hand fracture
chest discomfort
weakness
pain
nosebleed
oropharyngeal pain
speech disorder
allergic rhinitis
exertional dyspnea
wet cough
runny nose
lung mass
joint pain
osteoporosis
arthropathy
musculoskeletal discomfort
myositis
myalgia
soft tissue mass
postmenopausal osteoporosis
rotator cuff syndrome
male pattern baldness
hyperhidrosis
hair loss
dermatitis
anxiety
confusion
nocturia
dermatitis
hypertension
goiter
erectile dysfunction
dry eye
cataract
ocular discomfort
allergic conjunctivitis
vitreous hemorrhage
stomatitis
mediastinitis
ligament sprain
flank pain
myelodysplastic syndrome
vocal cord polyp
Not everyone experiences these, and they can vary from person to person.
Storage
This drug is sensitive to air and moisture; therefore, it must be stored in a tightly closed container during use. Additionally, it should be kept away from extreme heat or cold, ideally stored at room temperature between 1°C and 30°C.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.